vTv Therapeutics Inc.
NASDAQ: VTVT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul J. Sekhri
- Employees
- 23
- Headquarters
- High Point, United States
- IPO year
- 2015
- Market cap
- $93.5M
- Website
- https://www.vtvtherapeutics.com
Loading VTVT…
Loading profile data…Frequently asked questions about VTVT
What does vTv Therapeutics Inc. (VTVT) do?
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key i...
Where does VTVT trade?
vTv Therapeutics Inc. (VTVT) trades on the NASDAQ Capital Market.
What sector is VTVT in?
vTv Therapeutics Inc. (VTVT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of vTv Therapeutics Inc.?
Paul J. Sekhri is the chief executive officer of vTv Therapeutics Inc. (VTVT).
Where is vTv Therapeutics Inc. headquartered?
vTv Therapeutics Inc. is headquartered in United States.
Does VTVT pay a dividend?
vTv Therapeutics Inc. (VTVT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VTVT go public?
vTv Therapeutics Inc. (VTVT) completed its initial public offering in 2015.